Fig. 1 · Structure

Documents & Downloads

MGCD-265 analog

Cat. No. A10587 CAS 875337-44-3

c-Met inhibitor

MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Met IC50 1nM
RON IC50 2nM
VEGFR1 IC50 3nM
VEGFR2 IC50 3nM
VEGFR3 IC50 4nM
Tie-2 IC50 7nM

6 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
BTI-TN-5B1-4 IC50 0.037 μM Inhibition of GST-fused recombinant c-Met catalytic domain expressed in baculovirus-infected Trichoplusia ni Hi5 cells after 30 mins by DELFIA assay [PMID: 19211249]
HCC827 IC50 0.08 μM Antiproliferative activity against gefitinib resistant EGFR-mutated human HCC827 cells after 72 hrs by MTT assay [PMID: 28787156]
Sf9 IC50 0.026 μM Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay [PMID: 19211249]

MGCD-265 analog Research Summary

This section summarizes 2 in vitro studies of MGCD-265 analog from 2 published references. In vitro models include human GBC-SD, NOZ and SGC-996 gallbladder cancer cell lines.

MGCD-265 analog In Vitro Studies

In GBC-SD, NOZ and SGC-996 gallbladder cancer cells, the reported MGCD-265 analog reagent reduced the CCK-8 viability signal after 24 h, with IC50 values of 0.97 ± 0.2, 0.74 ± 0.15 and 0.75 ± 0.18 µM, respectively. These are cellular assay endpoints; the study does not establish selective MST1R inhibition. [1]

During ten-day exposure to 0.2, 0.8 or 3.2 µM of the reported reagent, GBC-SD, NOZ and SGC-996 cells showed reduced colony formation as concentration increased. The published stained wells support a qualitative response; numerical colony inhibition is not assigned. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

24-hour viability response in three gallbladder cancer cell lines

Cell-based study · Human GBC-SD, NOZ and SGC-996 gallbladder cancer cell lines [1,2]

The reported reagent reduced the CCK-8 viability signal in a concentration-dependent manner. IC50 values were below 1 µM in all three models. This metabolic viability endpoint does not establish a target-specific mechanism or clinical activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GBC-SD CCK-8 viability after 24 h exposureIC50 0.97 ± 0.2 µM[1]
NOZ CCK-8 viability after 24 h exposureIC50 0.74 ± 0.15 µM[1]
SGC-996 CCK-8 viability after 24 h exposureIC50 0.75 ± 0.18 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response experiment; exact series not transcribed. The values below are IC50 endpoints, not treatment concentrations.
Exposure duration
24 h drug exposure; CCK-8 readout after a further 4 h reagent incubation
Method
CCK-8 absorbance at 450 nm; five replicate wells per concentration and corresponding blank wells; Figure 2D normalized survival curves.
Reported limits
Drug vehicle and vehicle-matched control composition are not specified in the relevant methods. Figure 2D presents normalized survival; the normalization formula is not given. Methods state experiments were replicated three times, without defining independence.
Methods and source locations

Compound reported in the paper: MGCD-265 analog; Compound label in the paper: MGCD-265 (Selleck S1361)

Applies to experiments with the reported commercial analog reagent; does not validate an Adooq lot or establish equivalence to clinical glesatinib.

Figure 2C–D and associated Results (MST1R exhibits significant up-regulation...); Methods: CCK-8 assay, Cell culture, Statistical analysis; reagent identity: Western blot; Key Resources Table, physical PDF p. 17 (e2), Chemicals: glesatinib entry; SelleckChem S1361, CAS 875337-44-3. Reagent identity corroboration only; no experimental result adopted.

GBC-SD CCK-8 viability after 24 h exposure: CCK-8; reported ± values, with SD defined in general statistical methods. Five wells per concentration; experiments replicated three times according to general methods. — Figure 2C–D; associated Results; Methods: CCK-8 assay and Statistical analysis

NOZ CCK-8 viability after 24 h exposure: CCK-8; reported ± values, with SD defined in general statistical methods. Five wells per concentration; experiments replicated three times according to general methods. — Figure 2C–D; associated Results; Methods: CCK-8 assay and Statistical analysis

SGC-996 CCK-8 viability after 24 h exposure: CCK-8; reported ± values, with SD defined in general statistical methods. Five wells per concentration; experiments replicated three times according to general methods. — Figure 2C–D; associated Results; Methods: CCK-8 assay and Statistical analysis

Colony formation during ten-day exposure

Cell-based study · Human GBC-SD, NOZ and SGC-996 gallbladder cancer cell lines [1,2]

Colony formation declined with increasing concentrations of the reported reagent. Figure 2E supplies representative stained wells; no numerical colony counts or effect-size estimates are extracted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Colony formation after ten daysQualitative concentration response Reduced colony formation with increasing concentration relative to the labeled Control wells[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.2 µM, 0.8 µM and 3.2 µM; labeled Control wells
Exposure duration
10 days
Method
Colony formation assay; 400 cells per well and three replicate wells per group; Giemsa-stained colonies.
Reported limits
Control vehicle, drug replenishment schedule and numeric colony counts are not specified in the relevant assay description/figure. No percentage inhibition is estimated from plate images.
Methods and source locations

Compound reported in the paper: MGCD-265 analog; Compound label in the paper: MGCD-265 (Selleck S1361)

Applies to experiments with the reported commercial analog reagent; does not validate an Adooq lot or establish equivalence to clinical glesatinib.

Figure 2E and associated Results (MST1R exhibits significant up-regulation...); Methods: Colony formation assay, Cell culture, Statistical analysis; reagent identity: Western blot; Key Resources Table, physical PDF p. 17 (e2), Chemicals: glesatinib entry; SelleckChem S1361, CAS 875337-44-3. Reagent identity corroboration only; no experimental result adopted.

Colony formation after ten days: Colony formation assay; representative stained wells in Figure 2E; three replicate wells per group in Methods. — Figure 2E and associated Results (MST1R exhibits significant up-regulation...); Methods: Colony formation assay, Cell culture, Statistical analysis; reagent identity: Western blot

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 875337-44-3
Applications c-Met inhibitor
Formula C26H20FN5O2S2
Molecular Weight 517.6
SMILES
CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(=O)CC5=CC=CC=C5)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 99 mg/mL (191.26 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MGCD-265 analog Research References

  1. [1] Wei Wang, Chao Huang, Li Zhang, et al. MST1R-targeted therapy in the battle against gallbladder cancer. Cell & Bioscience (2024). PMID: 39210450 DOI: 10.1186/s13578-024-01290-w Source material
  2. [2] Oberlick EM, Rees MG, Seashore-Ludlow B, et al. Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Reports (2019). PMID: 31461650 DOI: 10.1016/j.celrep.2019.07.021 Source material

Added to your cart

View Cart Checkout
Loading...